2 results
8-K
EX-99.1
NMRD
Nemaura Medical Inc
13 Sep 23
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
8:03am
that affordability is a key barrier to CGM adoption, and the Company aims to price its CGM-embedded program significantly lower than any presently
8-K
EX-99.1
NMRD
Nemaura Medical Inc
16 Apr 19
Enhances Product Capabilities in Advance of CE Mark Approval
11:41am
, and the U.S. market alone is estimated at $13 billion1. Given that SugarBEAT® is non-invasive, coupled with its affordability and flexibility, the Company
- Prev
- 1
- Next